Drawing for BCN PEPTIDES

USPTO serial 79417399

BCN PEPTIDES

Reviewed by CopyMark Law Group

Status 694
Filing date
Status date
Registration date
—
Examiner
LATTUCA, FRANK J
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with BCN PEPTIDES?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Elizabeth Lee D'Amore

Elizabeth Lee D'Amore Lucas & Mercanti, LLP100 South Jefferson RoadSuite 202Whippany, NJ 07981

Goods and services

ClassDescriptionStatusFirst use
001Chemical products for use in industry specifically for biotechnological product development; chemical products for use in pharmaceutical product manufacture; chemical products for manufacturing cosmetics; biological preparations for industry and scienceACTIVE—
005Pharmaceutical products, namely, pharmaceutical preparations for the treatment of cardiovascular diseases, of the central nervous system, namely, encephalitis, epilepsy, alzheimer's, cerebral palsy, parkinson's disease, of respiratory diseases, namely, respiratory infections, asthma, bronchitis, pneumonia, of eating disorders, of musculo-skeletal disorders, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, of urological, urogenital and urinary disorders, of dermatological diseases, namely, dermatitis, skin pigmentation diseases, psoriasis, eczema, rosacea, blotches; pharmaceutical products for medical use to treat metabolic disorders, immune conditions and disorders, inflammatory conditions, pain, infectious diseases, oncological conditions, endocrine disorders, neurological disorders, cardiovascular diseases and disorders, hematological diseases, respiratory diseases, ophthalmic diseases, diseases of the digestive system, dermatological conditions and disorders, urological diseases, gynecological conditions and conditions of the reproductive system; pharmaceutical products for veterinary use, namely, veterinary pharmaceutical preparations for the treatment of metabolic disorders, immune conditions and disorders, inflammatory conditions, pain, infectious diseases, oncological conditions, endocrine disorders, neurological disorders, cardiovascular diseases and disorders, hematological diseases, respiratory diseases, ophthalmic diseases, diseases of the digestive system, dermatological conditions and disorders, urological diseases and conditions of the reproductive system; pharmaceutical products for skin care; hygienic and sanitary products for medical use namely, disinfectants and sanitary sterilizing preparations; dietetic substances for medical use; dietetic substances namely, dietetic preparations adapted for veterinary use, food supplements for humans and animals; biological preparations for medical and veterinary use specifically cytostatic agents, hormones, diagnostic agents for medical purposes, anti-infective agents, blood clotting agents, blood anticoagulant agents, , veterinary pharmaceutical preparations for the treatment of infectious diseases, namely, swine dysentery, bacterial enteritis, bluecomb, pneumonia, respiratory infections, eye infections, topical infectionsACTIVE—
042Scientific and technological services as well as research and design related thereto, namely, scientific research, development, and design services relating to pharmaceuticals; industrial analysis and research services in the field of chemistry for medical purposese; pharmaceutical research services; research and development services in chemistry; research services relating to cosmetics; pharmaceutical research and product development servicesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 8, 2026ISMRWITHDRAWN FROM ISSUE - MANAGING ATTORNEY REQUEST—
Sep 8, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 8, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 2, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 12, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 6, 2026OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Aug 3, 2026RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Jul 20, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jul 19, 2026OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Feb 3, 2026GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Feb 3, 2026GNSLLETTER OF SUSPENSION E-MAILED—
Feb 3, 2026CNSLSUSPENSION LETTER WRITTEN—
Feb 2, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 2, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 2, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 23, 2025RFNTREFUSAL PROCESSED BY IB—
Aug 1, 2025RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Aug 1, 2025RFRRREFUSAL PROCESSED BY MPU—
Jun 11, 2025RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jun 10, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 10, 2025DOCKASSIGNED TO EXAMINER—
Feb 24, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Feb 24, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 20, 2025REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance